Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Follow-up of INV-347 in Obesity
NCT07153172Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of INV-347 in obesity, sponsored by Novo Nordisk. Primary endpoint: Number of adverse events at 104 weeks. Started Aug 2025; status: recruiting.
02
Drugs
INV-347
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07153172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07153172.